当前位置: X-MOL 学术Int. J. Genom. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Identification of CPT1A as a Prognostic Biomarker and Potential Therapeutic Target for Kidney Renal Clear Cell Carcinoma and Establishment of a Risk Signature of CPT1A-Related Genes
International Journal of Genomics ( IF 2.9 ) Pub Date : 2020-08-18 , DOI: 10.1155/2020/9493256
Yingkun Xu, Guangzhen Wu, Xue Ma, Jianyi Li, Ningke Ruan, Zhiyu Zhang, Yalei Cao, Yougen Chen, Qi Zhang, Qinghua Xia

This study is aimed at investigating the expression, clinical significance, and biological role of CPT1A in kidney renal clear cell carcinoma (KIRC). We used the TCGA database and clinical pathology of tissue specimens to study the expression of CPT1A in KIRC. The expression of CPT1A in the kidney cancer tissue was significantly lower than that in the normal tissue. Survival curves demonstrated that the expression was correlated with prognosis in patients. We used the plasmid transfection method to explore the biological role of CPT1A in renal cancer cells and performed CCK-8, wound healing, and Transwell invasion experiments. The results demonstrated that CPT1A can inhibit the proliferation, migration, and invasion of renal cancer cells. Subsequently, we employed a bioinformatics analysis to further elucidate the role of CPT1A. The PPI network diagram was plotted, along with the coexpression diagram, between CPT1A and ten associated genes. The heat map was plotted, and the hazard ratio analysis of these eleven genes in KIRC was performed. Furthermore, the CPT1A, LPL, CPT2, and EHHADH genes were used to establish a reliable prognostic risk signature in KIRC. GSEA analysis demonstrated that CPT1A modulates tumor development via a variety of biological pathways in KIRC. We believe that CPT1A most likely suppresses tumor progression by employing tumor “slimming” in KIRC. Collectively, the results indicate the potential of CPT1A as a novel prognostic indicator and potential therapeutic target in KIRC.

中文翻译:

CPT1A的鉴定作为肾脏肾透明细胞癌的预后生物标志物和潜在治疗靶标,并建立与CPT1A相关的基因的风险特征

本研究旨在研究CPT1A在肾透明细胞癌(KIRC)中的表达,临床意义和生物学作用。我们使用TCGA数据库和组织标本的临床病理学来研究CPT1A在KIRC中的表达。CPT1A在肾癌组织中的表达明显低于正常组织。生存曲线表明该表达与患者的预后相关。我们使用质粒转染方法来探索CPT1A在肾癌细胞中的生物学作用,并进行了CCK-8,伤口愈合和Transwell入侵实验。结果表明,CPT1A可以抑制肾癌细胞的增殖,迁移和侵袭。随后,我们进行了生物信息学分析,以进一步阐明CPT1A的作用。在CPT1A和十个相关基因之间绘制了PPI网络图以及共表达图。绘制热图,并对KIRC中的这11个基因进行风险比分析。此外,使用CPT1A,LPL,CPT2和EHHADH基因在KIRC中建立可靠的预后风险特征。GSEA分析表明,CPT1A通过KIRC中的多种生物学途径调节肿瘤的发生。我们认为,CPT1A最有可能通过在KIRC中采用“减肥”来抑制肿瘤进展。总体而言,结果表明CPT1A作为KIRC中新的预后指标和潜在治疗靶标的潜力。并对KIRC中的这11个基因进行了风险比分析。此外,使用CPT1A,LPL,CPT2和EHHADH基因在KIRC中建立可靠的预后风险特征。GSEA分析表明,CPT1A通过KIRC中的多种生物学途径调节肿瘤的发生。我们认为,CPT1A最有可能通过在KIRC中采用“减肥”来抑制肿瘤进展。总体而言,结果表明CPT1A作为KIRC中新的预后指标和潜在治疗靶标的潜力。并对KIRC中的这11个基因进行了风险比分析。此外,使用CPT1A,LPL,CPT2和EHHADH基因在KIRC中建立可靠的预后风险特征。GSEA分析表明,CPT1A通过KIRC中的多种生物学途径调节肿瘤的发生。我们认为,CPT1A最有可能通过在KIRC中采用“减肥”来抑制肿瘤进展。总体而言,结果表明CPT1A作为KIRC中新的预后指标和潜在治疗靶标的潜力。我们认为,CPT1A最有可能通过在KIRC中采用“减肥”来抑制肿瘤进展。总体而言,结果表明CPT1A作为KIRC中新的预后指标和潜在治疗靶标的潜力。我们认为,CPT1A最有可能通过在KIRC中采用“减肥”来抑制肿瘤进展。总体而言,结果表明CPT1A作为KIRC中新的预后指标和潜在治疗靶标的潜力。
更新日期:2020-08-19
down
wechat
bug